Aplicación: Plataforma acelerada de desarrollo de líneas celulares que permite una rápida progresión desde el ADN hasta la sustancia farmacológica GMP para anticuerpos monoclonales
Sistema de expresión: Basado en la plataforma de expresión de mamíferos basada en CHO Selexis SUREtechnology
País de origen: Suiza; Estados Unidos

Otra información

Descripción adicional:

SUREmAb™, built on the Selexis® SUREtechnology Platform™, is KBI Biopharma's dedicated solution for rapid monoclonal antibody (mAb) development, designed to shorten timelines without sacrificing quality and take innovators from DNA to GMP drug substance in as little as 11 months. It offers an end-to-end service spanning cell line development, process development, and GMP manufacturing, transposase-based expression for high titers and consistent performance, standardized phase-appropriate workflows that speed IND-enabling work, and a design tailored specifically to mAb molecules with a strong track record across IgG subclasses, supporting both early-stage biotechs and companies scaling toward commercialization.